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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPERProvocative Testing for Coronary Reactivity and Spasm 103Melody Zaya, Puja K. Mehta, C. Noel Bairey Merz
Coronary spasm is an important etiology of chest pain, and it can lead to signiﬁcant adverse
outcomes for patients. Diagnosis is often difﬁcult due to the transient nature of the
symptoms. In this state-of-the-art paper, Zaya and colleagues review the role of and the
agents used for provocative testing in the diagnosis of coronary spasm.CLINICAL RESEARCH CLINICAL TRIALSFinal 1-Year Results of the CADUCEUS Trial 110
Konstantinos Malliaras, Raj R. Makkar, Rachel R. Smith, Ke Cheng, Edwin Wu,
Robert O. Bonow, Linda Marbán, Adam Mendizabal, Eugenio Cingolani, Peter V. Johnston,
Gary Gerstenblith, Karl H. Schuleri, Albert C. Lardo, Eduardo Marbán
Cardiosphere-derived cells (CDCs) were shown to exert regenerative effects at 6 months in
the CADUCEUS (CArdiosphere-Derived aUtologous Stem CElls to Reverse ventricUlar
dysfunction) trial. This paper reports on the 1-year results of that trial. Autologous CDCs
(12.5 to 25  106) grown from endomyocardial biopsies were intracoronarily infused in
17 patients with left ventricular dysfunction, 1.5 to 3 months after myocardial infarction.
A total of 8 patients were followed as routine-care controls. At 1 year, magnetic resonance
imaging revealed that the scar mass decreased and viable mass increased in CDC-treated
subjects but not in control patients. Scar shrinkage correlated with an increase in viability and
with an improvement in regional function. Safety endpoints were equivalent between groups.
The study concludes that intracoronary administration of autologous CDCs did not raise
statistically signiﬁcant safety concerns. Analysis of exploratory efﬁcacy endpoints revealed a
decrease in scar size, an increase in viable myocardium, and improved regional function of
infracted myocardium 1-year post-treatment.(continued on page A-32)
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Saul Blecker, Sunil K. Agarwal, Patricia P. Chang, Wayne D. Rosamond, Donald E. Casey,
Anna Kucharska-Newton, Martha J. Radford, Josef Coresh, Stuart Katz
This study compares the rates of compliance with care measures for hospitalized heart failure
patients with a principal discharge diagnosis of heart failure and those with another principal
discharge diagnosis. Patients with acute or chronic heart failure in the ARIC (Atherosclerosis
Risk in Communities) study surveillance areas were included. Of 4,345 hospitalizations of
heart failure patients, 39.6% carried a principal diagnosis of heart failure. Patients with
principal heart failure diagnosis had higher rates of left ventricular (LV) function assessment
(89.1% vs. 82.5%) and discharge angiotensin-converting enzyme (ACE) inhibition/
angiotensin receptor blockers (ARBs) in LV dysfunction (64.1% vs. 56.3%) as compared with
patients hospitalized for another cause. LV assessment and ACE inhibitor/ARB use was
associated with reductions in 1-year post-discharge mortality (adjusted odds ratios: 0.66 and
0.72, respectively), which did not differ for patients with versus without a principal heart
failure diagnosis. Blecker and colleagues conclude that, compared with individuals
hospitalized with a principal diagnosis of heart failure, heart failure patients hospitalized for
other causes were less likely to receive guideline-recommended care.
Editorial Comment: Robert O. Bonow, Mihai Gheorghiade, p. 131HEART RHYTHM DISORDERSICD Lead Failure in Children and Young Adults 133
Christopher M. Janson, Akash R. Patel, William J. Bonney, Karen Smoots, Maully J. Shah
This study aimed to investigate the impact of lead diameter and design on implantable
cardioverter-deﬁbrillator (ICD) lead survival in children and young adults. Lead performance
was reviewed in consecutive subjects age 30 years with transvenous right ventricular ICD
leads implanted. A total of 120 ICD leads were implanted in 101 patients at a median age of
15.5  21.9 years. There were 47 small-diameter (8 F) and 73 standard-diameter
(>8 F) leads. During a median follow-up of 28.7 months, there were 25 lead failures
(21% prevalence), with an incidence of 5.6% per year. The Sprint Fidelis (SF) leads
(Medtronic, Inc., Minneapolis, Minnesota) had lower 3-year (69% vs. 92%) and 5-year
(44% vs. 86%) survival probability than standard-diameter leads. Multivariate analysis
revealed that the SF design conferred the greatest hazard ratio (HR) for lead failure (HR:
4.42). In this single-center pediatric study that evaluated lead diameter, lead design, and
patient factors, the SF design conferred the highest risk of lead failure; this suggests that
design, rather than diameter, is the critical issue in ICD lead performance.(continued on page A-33)
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James A. Fallavollita, Brendan M. Heavey, Andrew J. Luisi, Jr, Suzanne M. Michalek,
Sunil Baldwa, Terry L. Mashtare, Jr, Alan D. Hutson, Robert A. deKemp, Michael S. Haka,
Munawwar Sajjad, Thomas R. Cimato, Anne B. Curtis, Michael E. Cain, John M. Canty, Jr
The PAREPET (Prediction of Arrhythmic Events with Positron Emission Tomography)
study tests the hypothesis that quantifying inhomogeneity in myocardial sympathetic
innervation could identify patients at the highest risk for sudden cardiac arrest (SCA). A total
of 204 subjects with ischemic cardiomyopathy (left ventricular ejection fraction [LVEF]
35%) underwent positron emission tomography (PET) to quantify myocardial sympathetic
denervation, perfusion, and viability. The primary endpoint was SCA (arrhythmic death or
implantable cardioverter-deﬁbrillator discharge for ventricular ﬁbrillation or ventricular
tachycardia). After 4.1 years of follow-up, cause-speciﬁc SCA was 16.2%. Infarct volume and
LVEF were not predictors of SCA. In contrast, patients developing SCA had a greater
amount of sympathetic denervation (33  10% vs. 26  11% of the left ventricle [LV]),
reﬂecting viable, denervated myocardium. Multivariable predictors of SCA were PET
sympathetic denervation, LV end-diastolic volume index, creatinine, and no angiotensin
inhibition. With optimized cut-points, the absence of all 4 factors indicated low risk for SCA
(44% of cohort, SCA <0.9%/year), whereas 2 factors indicated high risk for SCA (20% of
cohort, SCA 11.7%/year). Fallavollita and colleagues conclude that sympathetic denervation
assessed using 11C-meta-hydroxyephedrine PET predicts cause-speciﬁc mortality from SCA
independent of LVEF and infarct volume. This may be useful in identifying patients most
likely to beneﬁt from an ICD.
Editorial Comment: Frank M. Bengel, James T. Thackeray, p. 150HEART VALVE DISEASEBAV With Anomalous Cord 153Travis J. Vowels, Gonzalo V. Gonzalez-Stawinski, Jong M. Ko, Gregory D. Trachiotis,
Brad J. Roberts, Charles S. Roberts, William C. Roberts
This paper reports on 5 men who underwent aortic valve replacement for pure aortic
regurgitation (AR) associated with congenitally bicuspid aortic valve (BAV). Investigation
revealed an anomalous cord attaching the raphe of the conjoined cusp near its free margin to
the wall of the ascending aorta cephalad to the sinotubular junction. In 3 of 5 patients, the
anomalous cord appeared to cause chronic AR by preventing proper coaptation of the 2 aortic
valve cusps. In 2 patients, there was rupture of the anomalous cord causing acute severe AR.
Vowels and colleagues conclude that this variant of purely regurgitant BAV may cause
chronic AR (when the anomalous cord does not rupture) or acute severe AR (when the cord
ruptures).(continued on page A-34)
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Antoni Bayes-Genis, Marta de Antonio, Joan Vila, Judith Peñaﬁel, Amparo Galán,
Jaume Barallat, Elisabet Zamora, Agustin Urrutia, Josep Lupón
ST2 and galectin-3 (Gal-3) are biomarkers of myocardial ﬁbrosis and remodeling in heart
failure (HF). The 2 biomarkers were evaluated relative to conventional risk factors and
N-terminal pro–B-type natriuretic peptide (NT-proBNP) for long-term risk stratiﬁcation in
an ambulatory HF population. A total of 876 patients were included, with a median age of
70 years and median ejection fraction of 34%. Endpoints were 5-year all-cause and
cardiovascular mortality and combined all-cause death/HF hospitalization. During a median
follow-up of 4.2 years, 392 patients died. In a multivariate analysis, only ST2 remained
independently associated with cardiovascular mortality (hazard ratio: 1.27). Incorporation
of ST2 into a fully-adjusted model for all-cause mortality (including clinical variables and
NT-proBNP) improved discrimination (C-statistic: 0.77) and calibration, and it reclassiﬁed
patients signiﬁcantly better. This head-to-head comparison of 2 new-generation ﬁbrosis
biomarkers reveals the superiority of ST2 over Gal-3 in risk stratiﬁcation. The incremental
predictive contribution of Gal-3 to existing clinical risk factors was trivial.
Editorial Comment: James L. Januzzi, Jr, Roland R. J. van Kimmenade, p. 167BIOMARKERSBNP and Risk in Noncardiac Surgery 170
Reitze N. Rodseth, Bruce M. Biccard, Yannick Le Manach, Daniel I. Sessler, Giovana A. Lurati Buse,
Lehana Thabane, Robert C. Schutt, Daniel Bolliger, Lucio Cagini, Daniela Cardinale,
Carol P. W. Chong, Rong Chu, Miłosław Cnotliwy, Salvatore Di Somma, René Fahrner,
Wen Kwang Lim, Elisabeth Mahla, Ramaswamy Manikandan, Francesco Puma, Wook B. Pyun,
Milan Radovic, Sriram Rajagopalan, Stuart Suttie, Thuvaraha Vanniyasingam, William J. van Gaal,
Marek Waliszek, P. J. Devereaux
Rodseth and colleagues conduct a systematic review and individual patient data meta-analysis
to determine if measuring post-operative B-type natriuretic peptides (NP), enhances risk
stratiﬁcation in adult patients undergoing noncardiac surgery in whom pre-operative NPs
have been measured. The endpoint was a composite of death and nonfatal myocardial
infarction (MI) at 30 and 180 days after surgery. A total of 18 eligible studies provided
individual patient data (n ¼ 2,179). Results revealed that adding post-operative NPs to a risk
prediction model containing pre-operative NPs improved model ﬁt and risk classiﬁcation at
both 30 and 180 days. Elevated post-operative NP was the strongest independent predictor
of primary outcome at 30 days (odds ratio: 3.7) and 180 days (odds ratio: 2.2) after surgery.
This study shows that additional post-operative NP measurement enhances risk stratiﬁcation
for the composite outcome of death or nonfatal MI at both 30 and 180 days after
noncardiac surgery as compared with pre-operative NP measurement alone.
Editorial Comment: Aldo Clerico, Claudio Passino, Michele Emdin, p. 181
